Figure 8.

The difference between TENM2 mutant- and wild-type was analyzed via the CAMOIP website. According to checkpoints (a), neoantigens (b), and TMB (c) related analyses, the TENM2 mutated group enjoys a higher expression of PD-1 (PDCD1), neoantigens, and tumor mutation burden, which are all immunotherapy-contributed factors. (d) The ICPs are generally more active in the low-PTGS2 group. (e) Taking p value < 0.01 as significant, according to CIBERSORT TIC analysis, the macrophage M1, resting dendritic cells, activated dendritic cells, and activated mast cells show the discrepancy in differently PTGS2-expressed cohorts.